High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor-Reference-Cited by-同舟云学术

High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor

Published:1999-02 Issue:1-2 Volume:94 Page:15-27
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Tsantili Panayota,Tzartos Socrates J.,Mamalaki Avgi

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference56 articles.

1. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis;Asher;J. Immunol.,1993

2. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor;Barchan;Eur. J. Immunol.,1998

3. Mapping the main immunogenic region and toxin binding site of the nicotinic AChR;Barkas;Science,1987

4. Immunoglobulin swith hapten-binding activity: structure-function correlations and genetic implications;Barstad;Eur. J. Immunol.,1978

5. Functional cDNA libraries from Drosophila embryos;Brown;J. Mol. Biol.,1988

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure-Based Approaches to Antigen-Specific Therapy of Myasthenia Gravis;Selected Topics in Myasthenia Gravis;2019-06-12

2. High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates;European Journal of Pharmaceutical Sciences;2019-06

3. Heterogeneity of auto-antibodies against nAChR in myasthenic serum and their pathogenic roles in experimental autoimmune myasthenia gravis;Journal of Neuroimmunology;2018-07

4. Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravis;Muscle & Nerve;2012-04-12

5. Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy;Molecular Therapy;2010-09